Royalty Pharma Statistics
Share Statistics
Royalty Pharma has 433.44M
shares outstanding. The number of shares has increased by -4.15%
in one year.
| Shares Outstanding | 433.44M |
| Shares Change (YoY) | -4.15% |
| Shares Change (QoQ) | -2.47% |
| Owned by Institutions (%) | 71.53% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 75 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 20.57M, so 4.75% of the outstanding
shares have been sold short.
| Short Interest | 20.57M |
| Short % of Shares Out | 4.75% |
| Short % of Float | 4.82% |
| Short Ratio (days to cover) | 3.86 |
Valuation Ratios
The PE ratio is 13.29 and the forward
PE ratio is 6.29.
Royalty Pharma's PEG ratio is
-0.3.
| PE Ratio | 13.29 |
| Forward PE | 6.29 |
| PS Ratio | 5.04 |
| Forward PS | 3 |
| PB Ratio | 1.64 |
| P/FCF Ratio | 4.12 |
| PEG Ratio | -0.3 |
Financial Ratio HistoryEnterprise Valuation
Royalty Pharma has an Enterprise Value (EV) of 18.1B.
| EV / Sales | 8 |
| EV / EBITDA | 14.01 |
| EV / EBIT | 6.54 |
| EV / FCF | 6.54 |
Financial Position
The company has a current ratio of 1.44,
with a Debt / Equity ratio of 1.1.
| Current Ratio | 1.44 |
| Quick Ratio | 1.44 |
| Debt / Equity | 1.1 |
| Debt / EBITDA | 5.89 |
| Debt / FCF | 2.75 |
| Interest Coverage | 5.72 |
Financial Efficiency
Return on Equity is 12.37% and Return on Invested Capital is 4.64%.
| Return on Equity | 12.37% |
| Return on Assets | 4.71% |
| Return on Invested Capital | 4.64% |
| Revenue Per Employee | $30,186,666.67 |
| Profits Per Employee | $11,453,333.33 |
| Employee Count | 75 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 472M |
| Effective Tax Rate | 35.46% |
Stock Price Statistics
The stock price has increased by 13.76% in the
last 52 weeks. The beta is 0.48, so Royalty Pharma's
price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | 13.76% |
| 50-Day Moving Average | 32.52 |
| 200-Day Moving Average | 29.14 |
| Relative Strength Index (RSI) | 47.88 |
| Average Volume (20 Days) | 4,531,890 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of 2.26B
and earned 859M
in profits. Earnings per share was 1.92.
| Revenue | 2.26B |
| Gross Profit | 2.26B |
| Operating Income | 1.29B |
| Net Income | 859M |
| EBITDA | 1.29B |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | 1.92 |
Full Income StatementBalance Sheet
The company has 929.03M in cash and 7.61B in
debt, giving a net cash position of -6.68B.
| Cash & Cash Equivalents | 929.03M |
| Total Debt | 7.61B |
| Net Cash | -6.68B |
| Retained Earnings | 2.85B |
| Total Assets | 18.22B |
| Working Capital | 548.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 2.77B
and capital expenditures 0, giving a free cash flow of 2.77B.
| Operating Cash Flow | 2.77B |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.77B |
| FCF Per Share | 6.19 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of 57.07% and 37.94%.
| Gross Margin | 100% |
| Operating Margin | 57.07% |
| Pretax Margin | 58.79% |
| Profit Margin | 37.94% |
| EBITDA Margin | 57.07% |
| EBIT Margin | 57.07% |
| FCF Margin | 122.31% |
